GlassScriptPhysician profile
Nichole E Venzara
NPI 1043875545
$3,076.85
in general payments reported to CMS, 2019-2025
27 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $844 · 2023: $1,046 · 2024: $564 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,382.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $370.56 | 2021-2024 | Farxiga |
| Novo Nordisk INC | $200.71 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $178.07 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Biosense Webster, INC. | $138.05 | 2022 | |
| Glaxosmithkline, LLC. | $129.30 | 2021-2023 | |
| Pfizer INC. | $70.12 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $68.38 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $54.46 | 2022 | |
| Philips North America LLC | $45.69 | 2022-2023 | |
| Paratek Pharmaceuticals, INC. | $36.37 | 2025 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $36.33 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.25 | 2022-2023 | Jardiance |
| Sun Pharmaceutical Industries INC. | $33.51 | 2023-2024 | Ilumya |
| Novartis Pharmaceuticals Corporation | $30.17 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.99 | 2024 | Sotyktu |
| Bayer Healthcare Pharmaceuticals INC. | $29.41 | 2023 | |
| Amgen INC. | $28.05 | 2023 | Evenity, Prolia |
| Impulse Dynamics (USA) INC. | $25.24 | 2022 | |
| Abbott Laboratories | $24.93 | 2024 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $24.47 | 2023 | Dupixent |
| Journey Medical Corporation | $23.13 | 2024 | |
| Botanix Sb INC | $20.87 | 2025 | Sofdra |
| Boston Scientific Corporation | $19.82 | 2021 | |
| Galderma Laboratories, L.P. | $15.84 | 2023 | |
| Gilead Sciences, INC. | $13.51 | 2021 | |
| Phadia US INC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichole Venzara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.